CY1119843T1 - Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης - Google Patents
Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτηςInfo
- Publication number
- CY1119843T1 CY1119843T1 CY20171101334T CY171101334T CY1119843T1 CY 1119843 T1 CY1119843 T1 CY 1119843T1 CY 20171101334 T CY20171101334 T CY 20171101334T CY 171101334 T CY171101334 T CY 171101334T CY 1119843 T1 CY1119843 T1 CY 1119843T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ornithine
- phynyloxin
- production methods
- methods
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16667609P | 2009-04-03 | 2009-04-03 | |
| PCT/US2010/029708 WO2010115055A1 (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119843T1 true CY1119843T1 (el) | 2018-06-27 |
Family
ID=42828717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101334T CY1119843T1 (el) | 2009-04-03 | 2017-12-20 | Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US8173706B2 (enExample) |
| EP (4) | EP4101838A1 (enExample) |
| JP (6) | JP6144488B2 (enExample) |
| KR (6) | KR102399540B1 (enExample) |
| CN (3) | CN104230730B (enExample) |
| AU (1) | AU2010232521B2 (enExample) |
| BR (1) | BRPI1013657A2 (enExample) |
| CA (5) | CA2998434C (enExample) |
| CY (1) | CY1119843T1 (enExample) |
| DK (3) | DK2413924T3 (enExample) |
| EA (2) | EA034409B1 (enExample) |
| ES (3) | ES2791524T3 (enExample) |
| HR (2) | HRP20221232T8 (enExample) |
| HU (2) | HUE060371T2 (enExample) |
| IL (2) | IL215449B (enExample) |
| LT (2) | LT3686183T (enExample) |
| MX (4) | MX388894B (enExample) |
| NO (1) | NO2413924T3 (enExample) |
| NZ (3) | NZ708458A (enExample) |
| PL (2) | PL2413924T3 (enExample) |
| PT (2) | PT2413924T (enExample) |
| SG (3) | SG10201406300YA (enExample) |
| SI (1) | SI2413924T1 (enExample) |
| SM (2) | SMT202200395T1 (enExample) |
| WO (1) | WO2010115055A1 (enExample) |
| ZA (1) | ZA201107189B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2153870E (pt) | 2004-11-26 | 2014-03-12 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| NZ708458A (en) | 2009-04-03 | 2017-02-24 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| EA025735B1 (ru) | 2009-06-08 | 2017-01-30 | ЮСиЭл БИЗНЕС ПиЭлСи | Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата |
| US8068011B1 (en) | 2010-08-27 | 2011-11-29 | Q Street, LLC | System and method for interactive user-directed interfacing between handheld devices and RFID media |
| ES2720148T3 (es) * | 2010-10-06 | 2019-07-18 | Ocera Therapeutics Inc | Métodos de fabricación de fenilacetato de L-ornitina |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| CN105481725B (zh) * | 2014-09-18 | 2019-01-22 | 博瑞生物医药（苏州）股份有限公司 | L-精氨酸苯乙酸盐的晶型及其制备方法 |
| NZ732632A (en) | 2014-11-24 | 2021-07-30 | Ucl Business Ltd | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| EP3285756B1 (en) * | 2015-04-20 | 2023-02-22 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| JP6989495B2 (ja) * | 2015-09-25 | 2022-01-05 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防 |
| CA3004331A1 (en) * | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| KR20200024145A (ko) * | 2017-05-11 | 2020-03-06 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제조방법 |
| CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
| AR115585A1 (es) | 2018-06-20 | 2021-02-03 | Axcella Health Inc | Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo |
| JP2022533569A (ja) | 2019-05-09 | 2022-07-25 | オセラ セラピューティクス， インコーポレイテッド | 肝性脳症を評価および処置する方法 |
| CN110707221B (zh) * | 2019-09-25 | 2023-09-01 | 北京大学深圳研究生院 | 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用 |
| US20220362192A1 (en) * | 2019-10-16 | 2022-11-17 | Ocera Therapeutics, Inc. | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| WO2023240081A1 (en) * | 2022-06-06 | 2023-12-14 | Yale University | Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (enExample) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| US4100161A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| JP2522034B2 (ja) * | 1988-12-27 | 1996-08-07 | 味の素株式会社 | α−ケト酸・アミノ酸塩化合物及びその製造方法 |
| JPH03273578A (ja) | 1990-03-23 | 1991-12-04 | Ricoh Co Ltd | 対物レンズクリーニング装置 |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| DE4020980C1 (enExample) * | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| ATE153299T1 (de) | 1992-09-09 | 1997-06-15 | Fisons Plc | Pharmazeutisches verpacken |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US5856481A (en) | 1994-07-28 | 1999-01-05 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
| IL139728A (en) | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
| AU2251897A (en) | 1996-02-13 | 1997-09-02 | Trustees Of The University Of Pennsylvania, The | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| EP1179347A4 (en) | 1999-05-21 | 2002-06-26 | Takeda Chemical Industries Ltd | CONTROL SUBSTANCES FOR LIVER FUNCTION |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| DE60233558D1 (de) | 2001-03-15 | 2009-10-15 | Takashi Abe | Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| AU2003261825A1 (en) | 2002-08-30 | 2004-03-19 | Ajinomoto Co., Inc. | Therapeutic agent for hepatic disease |
| US20050059150A1 (en) * | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| AU2005216251B2 (en) * | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| KR20110124317A (ko) * | 2004-05-06 | 2011-11-16 | 오스테올로지스 에이에스 | 금속 유기 염의 제조를 위한 고 수율 및 고속 합성 방법 |
| WO2006059237A1 (en) | 2004-08-30 | 2006-06-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| PT2153870E (pt) * | 2004-11-26 | 2014-03-12 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| PT1948224E (pt) | 2005-11-17 | 2014-06-12 | Silverstone Pharma Est | Preparação industrial, e a sua utilização na terapêutica da hipertensão |
| NZ708458A (en) * | 2009-04-03 | 2017-02-24 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| EA025735B1 (ru) | 2009-06-08 | 2017-01-30 | ЮСиЭл БИЗНЕС ПиЭлСи | Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| JP2011236160A (ja) | 2010-05-11 | 2011-11-24 | Shinshu Univ | 非アルコール性肝疾患治療薬 |
| ES2720148T3 (es) | 2010-10-06 | 2019-07-18 | Ocera Therapeutics Inc | Métodos de fabricación de fenilacetato de L-ornitina |
| ES2654774T3 (es) | 2012-11-21 | 2018-02-15 | Horizon Therapeutics, Llc | Métodos para administrar y evaluar fármacos de recuperación de nitrógeno para el tratamiento de encefalopatía hepática |
| NZ732632A (en) | 2014-11-24 | 2021-07-30 | Ucl Business Ltd | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| EP3285756B1 (en) | 2015-04-20 | 2023-02-22 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| US10835506B2 (en) | 2015-08-18 | 2020-11-17 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
-
2010
- 2010-04-01 NZ NZ708458A patent/NZ708458A/en unknown
- 2010-04-01 MX MX2020009699A patent/MX388894B/es unknown
- 2010-04-01 DK DK10759442.6T patent/DK2413924T3/en active
- 2010-04-01 SG SG10201406300YA patent/SG10201406300YA/en unknown
- 2010-04-01 EA EA201500650A patent/EA034409B1/ru not_active IP Right Cessation
- 2010-04-01 PL PL10759442T patent/PL2413924T3/pl unknown
- 2010-04-01 NZ NZ619235A patent/NZ619235A/en unknown
- 2010-04-01 HU HUE20161306A patent/HUE060371T2/hu unknown
- 2010-04-01 HR HRP20221232TT patent/HRP20221232T8/hr unknown
- 2010-04-01 ES ES17185173T patent/ES2791524T3/es active Active
- 2010-04-01 KR KR1020217004211A patent/KR102399540B1/ko active Active
- 2010-04-01 CN CN201410392027.XA patent/CN104230730B/zh active Active
- 2010-04-01 HR HRP20171962TT patent/HRP20171962T1/hr unknown
- 2010-04-01 BR BRPI1013657A patent/BRPI1013657A2/pt not_active Application Discontinuation
- 2010-04-01 NO NO10759442A patent/NO2413924T3/no unknown
- 2010-04-01 KR KR1020207016586A patent/KR102217081B1/ko not_active Expired - Fee Related
- 2010-04-01 CA CA2998434A patent/CA2998434C/en active Active
- 2010-04-01 EP EP22185562.0A patent/EP4101838A1/en active Pending
- 2010-04-01 MX MX2011010262A patent/MX2011010262A/es active IP Right Grant
- 2010-04-01 SM SM20220395T patent/SMT202200395T1/it unknown
- 2010-04-01 NZ NZ595706A patent/NZ595706A/en unknown
- 2010-04-01 AU AU2010232521A patent/AU2010232521B2/en active Active
- 2010-04-01 SM SM20170601T patent/SMT201700601T1/it unknown
- 2010-04-01 EP EP17185173.6A patent/EP3263100B1/en active Active
- 2010-04-01 KR KR1020227016294A patent/KR20220067001A/ko not_active Abandoned
- 2010-04-01 PT PT107594426T patent/PT2413924T/pt unknown
- 2010-04-01 CA CA2998344A patent/CA2998344C/en active Active
- 2010-04-01 ES ES20161306T patent/ES2928586T3/es active Active
- 2010-04-01 SG SG10202010988WA patent/SG10202010988WA/en unknown
- 2010-04-01 KR KR1020197012203A patent/KR102123243B1/ko active Active
- 2010-04-01 ES ES10759442.6T patent/ES2652187T3/es active Active
- 2010-04-01 KR KR1020117026256A patent/KR101844605B1/ko active Active
- 2010-04-01 DK DK17185173.6T patent/DK3263100T3/da active
- 2010-04-01 KR KR1020187008530A patent/KR101975726B1/ko active Active
- 2010-04-01 JP JP2012503725A patent/JP6144488B2/ja active Active
- 2010-04-01 MX MX2014008993A patent/MX356608B/es unknown
- 2010-04-01 SG SG2011071164A patent/SG174982A1/en unknown
- 2010-04-01 PT PT201613064T patent/PT3686183T/pt unknown
- 2010-04-01 EP EP20161306.4A patent/EP3686183B1/en active Active
- 2010-04-01 CA CA3205755A patent/CA3205755A1/en active Pending
- 2010-04-01 CA CA3077846A patent/CA3077846C/en active Active
- 2010-04-01 WO PCT/US2010/029708 patent/WO2010115055A1/en not_active Ceased
- 2010-04-01 CA CA2757373A patent/CA2757373C/en active Active
- 2010-04-01 CN CN201710053850.1A patent/CN106810464B/zh active Active
- 2010-04-01 PL PL20161306.4T patent/PL3686183T3/pl unknown
- 2010-04-01 DK DK20161306.4T patent/DK3686183T3/da active
- 2010-04-01 MX MX2018006692A patent/MX375111B/es unknown
- 2010-04-01 CN CN201080021311.6A patent/CN102421432B/zh active Active
- 2010-04-01 LT LTEP20161306.4T patent/LT3686183T/lt unknown
- 2010-04-01 EP EP10759442.6A patent/EP2413924B1/en active Active
- 2010-04-01 HU HUE10759442A patent/HUE035921T2/en unknown
- 2010-04-01 SI SI201031596T patent/SI2413924T1/en unknown
- 2010-04-01 EA EA201171216A patent/EA023051B1/ru not_active IP Right Cessation
- 2010-04-01 LT LTEP10759442.6T patent/LT2413924T/lt unknown
- 2010-04-02 US US12/753,763 patent/US8173706B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 ZA ZA2011/07189A patent/ZA201107189B/en unknown
- 2011-10-02 IL IL215449A patent/IL215449B/en active IP Right Grant
-
2012
- 2012-03-30 US US13/436,642 patent/US8492439B2/en active Active
-
2013
- 2013-07-08 US US13/937,107 patent/US8785498B2/en active Active
-
2014
- 2014-06-09 US US14/299,940 patent/US9034925B2/en active Active
-
2015
- 2015-02-20 JP JP2015031199A patent/JP6010154B2/ja active Active
- 2015-05-18 US US14/715,481 patent/US9604909B2/en active Active
-
2016
- 2016-12-07 JP JP2016237164A patent/JP6328737B2/ja active Active
-
2017
- 2017-03-24 US US15/469,359 patent/US10173964B2/en active Active
- 2017-12-20 CY CY20171101334T patent/CY1119843T1/el unknown
-
2018
- 2018-04-18 JP JP2018079490A patent/JP6647336B2/ja not_active Expired - Fee Related
- 2018-07-17 US US16/037,655 patent/US10550069B2/en active Active
- 2018-12-18 IL IL263784A patent/IL263784A/en unknown
-
2020
- 2020-01-14 JP JP2020003346A patent/JP7086118B2/ja active Active
- 2020-01-31 US US16/778,696 patent/US11161802B2/en active Active
-
2022
- 2022-03-25 JP JP2022049427A patent/JP2022088504A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119843T1 (el) | Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1122123T1 (el) | Συνθεσεις λιπιδικου νανοσωματιδιου και μεθοδοι για απελευθερωση mrna | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1123958T1 (el) | Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης | |
| CY1120337T1 (el) | Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης | |
| CY1122639T1 (el) | Παραγωγα 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου ως ενδιαμεσα στην παρασκευη παραγωγων [(5-αλογονοφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)- αμινο]αλκανοϊκου οξεος | |
| CY1122580T1 (el) | Χημικη συνθεση χρησιμη ως ενδιαμεσο για την παρασκευη ενος αναστολεα κατεχολ-ο-μεθυλοτρανσφερασης | |
| CY1122964T1 (el) | Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων | |
| CY1116315T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
| CY1122218T1 (el) | Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης | |
| CY1121204T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige | |
| CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
| CY1115945T1 (el) | Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση | |
| CY1116455T1 (el) | Υποκατεστημενα 4-αρυλο-1,4-διυδρο-1,6-ναφθυριδιν αμιδια και η χρηση τους | |
| CY1119200T1 (el) | Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες | |
| CY1116700T1 (el) | Παρασκευη συνθετικου χολικου οξεος | |
| UY33970A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
| CY1120008T1 (el) | Βενζαμιδια | |
| MX375715B (es) | Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos. | |
| CY1110962T1 (el) | Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων | |
| CY1117933T1 (el) | Συνθεσεις ξηρας ψυξης toy fgf-18 | |
| CY1111954T1 (el) | Παραγωγα τετραϋδροναφθαλινιου, μεθοδοι για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδη | |
| CY1116984T1 (el) | ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2 |